What is the Market's View on Xilio Therapeutics Inc (XLO) Stock's Price and Volume Trends Friday?

Overall market sentiment has been high on Xilio Therapeutics Inc (XLO) stock lately. XLO receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Xilio Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on XLO!

See Full XLO Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With XLO Stock Today?

Xilio Therapeutics Inc (XLO) stock is trading at $4.20 as of 2:17 PM on Friday, Jan 27, a gain of $0.07, or 1.69% from the previous closing price of $4.13. The stock has traded between $3.95 and $4.20 so far today. Volume today is 74,211 compared to average volume of 67,062. To screen for more stocks like Xilio Therapeutics Inc click here.

More About Xilio Therapeutics Inc

Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index. Click Here to get the full Stock Report for Xilio Therapeutics Inc stock.